July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program
Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise through an undisclosed clinical inflection point. Financial terms are undisclosed. The companies initially partnered in 2017 for Nimbus' TYK2 and STING programs (see "Nimble Move" & "Kinase Identified as New Cancer Immunotherapy Target").

Gilead, Lyndra to develop long-acting HIV therapies
Gilead Sciences Inc. (NASDAQ:GILD) gained exclusive rights from Lyndra Therapeutics Inc. (Watertown, Mass.) to use its capsule delivery platform to develop long-acting oral HIV therapies. Financial terms are undisclosed. Gilead participated in Lyndra's $60.9 million series B in January (see "Lyndra Raises Series B")...